VDAC1 and cancer: Also, the VDAC inhibitor, JQ1, prevents the activity of bromodomain-containing proteins (BRD), including BRD4, that is enriched in patients with basal luminal breast cancer (Qi, 2014), suggesting that VDAC1 is relevant in cancer cell progression and is a hallmark of poor prognosis (Yang et al., 2019).